LABCORP HOLDINGS INC. Finite-lived Intangible Assets Acquired
LABCORP HOLDINGS INC. (LH) reported Finite-lived Intangible Assets Acquired of $288.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2026-08-05
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for the quarter ending 2026-06-30 was $122.80M.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for the quarter ending 2026-03-31 was $165.40M.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for the quarter ending 2022-12-31 was $134.90M, a 140.89% increase year-over-year.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for the quarter ending 2022-09-30 was $82.10M, a 34.27% decline year-over-year.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for fiscal 2025 was $315.90M, a 28.25% decline from fiscal 2024.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for fiscal 2024 was $440.30M, a 29.20% increase from fiscal 2023.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for fiscal 2023 was $340.80M, a 37.16% decline from fiscal 2022.
- LABCORP HOLDINGS INC. finite-lived intangible assets acquired for fiscal 2022 was $542.30M, a 173.20% increase from fiscal 2021.
| Period end | Finite-lived Intangible Assets Acquired 3 month | Finite-lived Intangible Assets Acquired 6 month | Finite-lived Intangible Assets Acquired 9 month | Finite-lived Intangible Assets Acquired 12 month | Finite-lived Intangible Assets Acquired 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $122.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $288.20M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $165.40M 10-Q · filed 2026-05-04 | ||||
| 2025-12-31 | $315.90M 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $440.30M 10-K · filed 2026-02-24 | $477.30M 10-K · filed 2025-02-25 | |||
| 2023-12-31 | $340.80M 10-K · filed 2026-02-24 | $313.90M 10-K · filed 2024-02-26 | |||
| 2022-12-31 | $134.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $217.00M derived: sum of 2 quarters · filed 2024-02-26 | $272.30M derived: sum of 3 quarters · filed 2024-02-26 | $542.30M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $82.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $137.40M derived: sum of 2 quarters · filed 2022-11-01 | $407.40M 10-Q · filed 2022-11-01 | $463.40M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $55.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $325.30M 10-Q · filed 2022-08-01 | $381.30M derived: sum of 3 quarters · filed 2024-02-26 | $506.20M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $270.00M 10-Q · filed 2022-04-29 | $326.00M derived: sum of 2 quarters · filed 2024-02-26 | $450.90M derived: sum of 3 quarters · filed 2024-02-26 | $450.90M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | $56.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $180.90M derived: sum of 2 quarters · filed 2024-02-26 | $180.90M derived: sum of 3 quarters · filed 2024-02-26 | $198.50M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $124.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $124.90M derived: sum of 2 quarters · filed 2021-11-02 | $142.50M 10-Q · filed 2021-11-02 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $17.60M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $17.60M 10-Q · filed 2021-05-04 | ||||
| 2020-12-31 | $121.30M 10-K · filed 2022-02-25 | ||||
| 2019-12-31 | $184.30M 10-K · filed 2021-02-25 | $325.90M 10-K · filed 2020-02-28 | |||
| 2019-03-31 | $24.80M 10-Q · filed 2019-05-03 | $44.10M derived: sum of 2 quarters · filed 2020-02-28 | $44.10M derived: sum of 3 quarters · filed 2020-02-28 | ||
| 2018-12-31 | $19.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $19.30M derived: sum of 2 quarters · filed 2020-02-28 | $67.80M 10-K · filed 2020-02-28 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $48.50M 10-Q · filed 2018-10-30 | |||
| 2018-06-30 | $48.50M 10-Q · filed 2018-07-27 | ||||
| 2017-12-31 | $1.05B 10-K · filed 2018-02-27 | ||||
| 2016-12-31 | $272.80M 10-K · filed 2017-02-27 | ||||
| 2015-12-31 | $2.18B 10-K · filed 2016-03-01 | ||||
| 2014-12-31 | $38.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $38.10M derived: sum of 2 quarters · filed 2015-02-26 | $38.10M derived: sum of 3 quarters · filed 2015-02-26 | $53.70M 10-K · filed 2015-02-26 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $15.60M 10-Q · filed 2014-11-10 | $29.50M derived: sum of 4 quarters · filed 2014-11-10 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $15.60M 10-Q · filed 2014-07-29 | $29.50M derived: sum of 3 quarters · filed 2014-07-29 | ||
| 2014-03-31 | $15.60M 10-Q · filed 2014-04-29 | $29.50M derived: sum of 2 quarters · filed 2014-04-29 | |||
| 2013-12-31 | $13.90M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $40.90M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $27.00M 10-Q · filed 2013-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |